On 11 March 2020, the World Health Organization declared COVID-19 a pandemic. The impact on the medical community has been huge, not only on the front-line but also for patients navigating treatment for existing conditions during this unprecedented situation. Research into vaccines and treatments to protect against COVID-19 has been instrumental in controlling the pandemic.
The touchINFECTIOUS DISEASES expert faculty have been sharing their experiences and advice during this challenging time through video interviews and short articles.
Paul Heath: UK Approves Nuvaxovid COVID-19 Vaccine
Novavax’s COVID-19 vaccine, Nuvaxovid, has been authorised for use in the UK for those aged 18 and over. Prof. Paul Heath (St George’s, University of London, London, UK) kindly met with touchINFECTIOUS DISEASES to discuss the Novavax vaccine (Nuvaxovid), the clinical evidence in support of its use and the impact on the COVID-19 vaccination program in the UK.
Nagalingeswaran Kumarasamy, CROI 2022: Management and Treatment of COVID-19
Dr N Kumarasamy (Voluntary Health Services Hospital, Chennai, Southern India) joins us at CROI 2022, to discuss the potential tools available for the management and treatment of COVID-19.
Nagalingeswaran Kumarasamy, CROI 2022: Phase III Trial of Molnupiravir in Adults with COVID-19 in India
Molnupiravir was developed in response to an urgent unmet need for an orally administered antiviral drug to prevent disease progression in patients with COVID-19. Dr Nagalingeswaran Kumarasamy (Voluntary Health Services Hospital, Chennai, Southern India) discusses the phase III study assessing the efficacy and safety of molnupiravir in Indian patients with mild SARS-CoV2 infection.
Nikolaus Jilg, CROI 2022: Camostat is not Effective for Mild-to-moderate COVID-19 in a Phase II Trial of ACTIV-2
The phase 2 ACTIV-2 findings (NCT30318759), investigating camostat for Mild-Moderate COVID-19 were discussed in this short interview with Dr Nikolaus Jilg (Massachusetts General Hospital, Boston, MA, USA). Camostat is a serine protease inhibitor, and prevents activation of the SARS-CoV-2 spike protein and blocks SARS-CoV-2 infection in vitro. Dr Jilg and colleagues studied the safety and antiviral and clinical efficacy of orally administered camostat in non-hospitalized adults with mild-moderate COVID-19.
Novavax Phase 3 Program of Clinical trials evaluating NVX-CoV2373 across the US, South Africa and UK [Part 2]
It was a great pleasure to meet with Prof. Paul Heath (St George’s, University of London, London, UK) to discuss the findings from the Novavax program of clinical trials evaluating the safety and efficacy of NVX-CoV2373 across the US, South Africa and the UK. Please find Part 1 of this interview available here.
Phase 3 trial of Novavax Investigational COVID-19 vaccine [Part 1]
It was a great pleasure to meet with Prof. Paul Heath (St George’s, University of London, London, UK) to discuss the findings from the Phase III Novavax clinical trial that is investigating the safety and efficacy of NVX-CoV2373, a vaccine candidate for COVID-19. Please find Part 2 of this interview available here.
Phase 3 SAVE-MORE Study Results Investigating Anakinra in the Treatment of Severe COVID-19
It was a great pleasure to meet with Prof. Evangelos Giamarellos-Bourboulis (Attikon University Hospital, Athens, Greece) to discuss phase 3 SAVE-MORE study assessing the effect of anakinra for the treatment of patients with COVID-19 pneumonia.
Phase 2 Trial Results Investigating Fostamatinib for the treatment of COVID-19
It was a great pleasure to meet with Jeffrey Strich (National Institutes of Health Clinical Center, Bethesda, MD, USA) to discuss the findings from a recent phase 2 study investigating fostamatinib for the treatment of hospitalized adults with COVID-19.
ECCMID 2021: ATOMIC2 Study Results
touchINFECTIOUSDISEASES were pleased to meet with Timothy Hinks (Nuffield Department of Medicine, University of Oxford, Oxford, UK) to discuss the results of the ATOMIC2 study results, investigating azithromycin in the treatment of COVID-19.
COVID-19 in clinical practice
Dr Tiwaskar and Dr Kinra share their experiences of managing patients at the onset of the COVID-19 pandemic and the key lessons learnt in clinical practice within India and the UK.
HIVR4P 2021: T Cell Responses of SARS-CoV-2 Epitopes
We were delighted to have the opportunity to speak with Dr Alba Grifoni ( La Jolla Institute for Immunology, La Jolla, CA, USA) to discuss T Cell responses of SARS-CoV-2 epitopes in COVID-19 cases.
ISNTD d3 2021: Ivermectin for COVID-19
It was a delight to be able to speak with Dr Carlos Chaccour (University of Barcelona, Barcelona, Spain) about the controversy currently surrounding the use of ivermectin for the treatment of COVID-19.
EASL ILC 2021: Tenofovir in Hepatitis B Patients with COVID-19
It was lovely to speak with Dr Beatriz Mateos (Universidad de Alcalá, Madrid, Spain) about the findings from her research into the impact of tenofovir on the severity of COVID-19 infection in those with chronic hepatitis B.
Mucormycosis: What is it and how can it be avoided in patients with COVID-19
Prof. Partha Kar, Dr Syed Shoeb Ahmad and Dr Neil Stone share their insights into the risk factors for mucormycosis in patients with COVID-19 and how it can be avoided.
COVID-19: How can transmission be prevented and controlled?
Join Dr Sanjay Kalra as he discusses viral transmission in COVID-19 and strategies to prevent transmission.
Education activities are developed by touchIME for touchINFECTIOUS DISEASES.
Our education resources are developed in collaboration with our well established peer-reviewed medical journals, our Editorial Board members and partnerships with major medical societies, with a clear commitment to high-quality independent education.
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!